Personalized medicine for prevention: can risk stratified screening decrease colorectal cancer mortality at an acceptable cost?

Cancer Causes and Control

Volumn 28, Issue 4, 2017, Pages 299-308

  Subramanian, Sujha ^a   Bobashev, Georgiy ^a   Morris, Robert J ^a   Hoover, Sonja ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

Colorectal cancer; Cost effectiveness; Precision medicine; Prevention; Risk stratification

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; HARM REDUCTION; HEALTH CARE PLANNING; HEALTH SURVEY; HUMAN; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; RISK ASSESSMENT; SIMULATION; UNITED STATES; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; MORTALITY;

COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; HUMANS; PRECISION MEDICINE; RISK ASSESSMENT;

EID: 85013478481     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-017-0864-4     Document Type: Article

References (35)

1. U.S. Cancer Statistics Working Group (2014) United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. 2014 http://www.cdc.gov/uscs
2. National Colorectal Cancer Roundtable (2015) 80% screening rate by 2018. http://nccrt.org/tools/80-percent-by-2018. Accessed 22 Aug 2015
3. Knudsen AB, Zauber AG, Rutter CM et al (2016) Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US preventive services task force. JAMA 315(23):2595–2609. doi:10.1001/jama.2016.68282529493
4. Bibbins-Domingo K, Grossman DC, Curry SJ et al (2016) Screening for colorectal cancer: us preventive services task force recommendation statement. JAMA 315(23):2564–2575. doi:10.1001/jama.2016.59892529486
5. Lin JS, Piper MA, Perdue LA et al (2016) Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 315(23):2576–2594. doi:10.1001/jama.2016.33322529492
6. Sabatino S, White M, Thompson T, Klabunde C (2013) Centers for disease control and prevention (CDC). Cancer screening test use—United States, 2013. MMWR 64(17):464–468
7. Fisher JA, Fikry C, Troxel AB (2006) Cutting cost and increasing access to colorectal cancer screening: another approach to following the guidelines. CEBP 15(1):108–113
8. Subramanian S, Bobashev G, Morris RJ (2010) When budgets are tight, there are better options than colonoscopies for colorectal cancer screening. Health Aff 29(9):1734–1740
9. Gupta S, Sussman DA, Doubeni CA, Anderson DS, Day L, Deshpande AR et al (2014) Challenges and possible solutions to colorectal cancer screening for the underserved. JNCI 106(4):dju032
10. ®). http://www.cancer.gov/types/colorectal/hp/colorectal-genetics-pdq#section/_1. Accessed 20 June 2015
11. Scheuner MT, McNeel TS, Freedman AN (2010) Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California health interview survey. Genet Med 12(11):726–735
12. Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der Klift H, Mulder A, et al (1998) Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. NEJM 339(8):511–518
13. Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann BJ, Pee D et al (2009) Colorectal cancer risk prediction tool for white men and women without known susceptibility. JCO 27(5):686–693
14. Park Y, Freedman AN, Gail MH, Willis G, Cann BJ, Pee D et al (2009) Validation of a colorectal cancer risk prediction model among white patients age 50 years and older. JCO 27(5):694–698
15. Ma GK, Ladabaum U (2014) Personalizing colorectal cancer screening: a systematic review of models to predict risk of colorectal neoplasia. Clin Gastroenterol Hepatol 1624–1634(10):e1621
16. Wells BJ, Kattan MW, Cooper GS, Jackson L, Koroukian S (2014) Colorectal cancer predicted risk online (CRC-PRO) calculator using data from the multi-ethnic cohort study. JABFM 27(1):42–55
17. rd (2011) Performance of a risk index for advanced proximal colorectal neoplasia among a racially/ethnically diverse patient population. Am J Gastroenterol 106(6):1099–1106
18. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM (2000) Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284(15):1954–1961
19. Ladabaum U, Song K (2005) Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 129(4):1151–1162
20. Subramanian S, Bobashev G, Morris RJ (2009) Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance. CEBP 18(7):1971–1978
21. Agrawal S, Bhupinderjit A, Bhutani MS, Boardman L, Nguyen C, Romero Y et al (2005) Colorectal cancer in African Americans. Am J Gastroenterol 100(3):515–523. (discussion 514)
22. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Winawer SJ et al (2009) Individualizing colonoscopy screening by sex and race. Gastrointest Endosc 96–108(108):e101–e124
23. Muc-Wierzgon M, Nowakowska-Zajdel E, Dziegielewska-Gesiak S, Kokot T, Klakla K, Fatyga E et al (2014) Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. World J Gastroenterol 20(29):9759–9774
24. Ramsey SD, Burke W, Pinsky L, Clarke L, Newcomb P, Khoury MJ (2005) Family history assessment to detect increased risk for colorectal cancer: conceptual considerations and a preliminary economic analysis. CEBP 14(11 Pt 1):2494–2500
25. Hubbard RA, Johnson E, Hsia R, Rutter CM (2013) The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening. CEBP 22(9):1612–1619
26. Pignone M, Russell L, Wagner J (eds) (2005) Economic models of colorectal cancer screening in average-risk adults: workshop summary. Institute of medicine and national research council, Washington DC, USA
27. Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM (2007) Cost-effectiveness of DNA stool testing to screen for Colorectal cancer. AHRQ Technology Assessment, Rockville, Maryland, USA
28. Ness RM, Holmes AM, Klein R, Dittus R (2000) Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. AJG 95(7):1800–1811
29. Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND et al (2014) American society of clinical oncology expert statement: collection and use of a cancer family history for oncology providers. JCO 32(8):833–840
30. Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161
31. Doerr M, Teng K (2012) Family history: still relevant in the genomics era. Cleve Clin J Med 79(5):331–336
32. Stalmeier PF, Lamers LM, Busschbach JJ, Krabbe PF (2007) On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences. Med Care 45(9):835–841
33. Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA et al (2012) Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308(15):1555–1565
34. Cook-Deegan R, Heaney C (2010) Patents in genomics and human genetics. Annu Rev Genomics Hum Genet 11:383–425
35. Mvundura M, Grosse SD, Hampel H, Palomaki GE (2010) The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 12(2):93–104